Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
| Author | |
|---|---|
| Abstract |
:
Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic malignancies. |
| Year of Publication |
:
2018
|
| Journal |
:
Gynecologic oncology
|
| Date Published |
:
2018
|
| ISSN Number |
:
0090-8258
|
| URL |
:
http://linkinghub.elsevier.com/retrieve/pii/S0090-8258(17)31620-7
|
| DOI |
:
10.1016/j.ygyno.2017.12.029
|
| Short Title |
:
Gynecol Oncol
|
| Download citation |
